CytoMed Therapeutics Limited (GDTC) vs IN8bio, Inc. (INAB)
Over the past 3 years, INAB lagged GDTC — -63.57% vs -34.77% annualized total return (price plus dividends).
A side-by-side comparison of CytoMed Therapeutics Limited and IN8bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — GDTC vs INAB
growth of $100 · dividends reinvested · last 3yMetrics side by side
Did INAB beat GDTC?
Over the past 3 years, INAB lagged GDTC — -63.57% vs -34.77% annualized total return (price plus dividends).
Total return (annualized)
| Metric | GDTC | INAB |
|---|---|---|
| Total return (1Y) | -49.59% | -40.44% |
| Total return CAGR (3Y) | -34.77% | -63.57% |
| Total return CAGR (5Y) | N/A | -62.88% |
GDTC is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has INAB beaten GDTC?
- Over the past 3 years, INAB lagged GDTC — -63.57% vs -34.77% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.